MXPA04005364A - Clones de acido desoxirribonucleico infeccioso quimericos, circovirus de porcino quimericos y usos de los mismos. - Google Patents

Clones de acido desoxirribonucleico infeccioso quimericos, circovirus de porcino quimericos y usos de los mismos.

Info

Publication number
MXPA04005364A
MXPA04005364A MXPA04005364A MXPA04005364A MXPA04005364A MX PA04005364 A MXPA04005364 A MX PA04005364A MX PA04005364 A MXPA04005364 A MX PA04005364A MX PA04005364 A MXPA04005364 A MX PA04005364A MX PA04005364 A MXPA04005364 A MX PA04005364A
Authority
MX
Mexico
Prior art keywords
chimeric
dna clones
pcv1
infectious
nonpathogenic
Prior art date
Application number
MXPA04005364A
Other languages
English (en)
Inventor
Fenaux Martijn
Original Assignee
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa State Res Found Inc filed Critical Univ Iowa State Res Found Inc
Publication of MXPA04005364A publication Critical patent/MXPA04005364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a clones de ADN infecciosos, clones de ADN quimericos infecciosos de circovirus de porcino (PCV), vacunas y medios de proteccion de cerdos contra infeccion viral o sindrome de debilitamiento multisistemico de post-destete (PMWS) causado por PCV2. El clon de ADN infeccioso quimerico novedoso y su derivado, un virus quimerico virulento se construyen a partir de PCV1 no patogenico en el cual el gen de ORF imnunogenico del PCV2 patogenico reemplaza a un gen del PCV1 no patogenico, preferiblemente en la misma posicion. El virus quimerico ventajosamente retiene el fenotipo no patogenico de PCV1 pero induce respuestas inmunes especificas contra el PCV2 patogenico. La invencion ademas abarca los productos de expresion del polipeptido inmunogenico.
MXPA04005364A 2001-12-12 2002-12-11 Clones de acido desoxirribonucleico infeccioso quimericos, circovirus de porcino quimericos y usos de los mismos. MXPA04005364A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34077501P 2001-12-12 2001-12-12
US42484002P 2002-11-08 2002-11-08
US10/314,512 US7276353B2 (en) 2001-12-12 2002-12-09 Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
PCT/US2002/039646 WO2003049703A2 (en) 2001-12-12 2002-12-11 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof

Publications (1)

Publication Number Publication Date
MXPA04005364A true MXPA04005364A (es) 2004-09-27

Family

ID=27405726

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005364A MXPA04005364A (es) 2001-12-12 2002-12-11 Clones de acido desoxirribonucleico infeccioso quimericos, circovirus de porcino quimericos y usos de los mismos.

Country Status (31)

Country Link
US (1) US7276353B2 (es)
EP (5) EP1487483B1 (es)
JP (1) JP4623964B2 (es)
KR (1) KR101014544B1 (es)
CN (2) CN1620310B (es)
AT (1) ATE487490T1 (es)
AU (3) AU2002362147C1 (es)
BE (1) BE2011C008I2 (es)
BR (1) BRPI0214919B1 (es)
CA (2) CA2469599C (es)
CO (1) CO5590938A2 (es)
CY (3) CY1111167T1 (es)
DE (2) DE122011100001I1 (es)
DK (3) DK1487483T3 (es)
ES (3) ES2529726T3 (es)
FR (1) FR11C0014I2 (es)
HK (1) HK1151988A1 (es)
HR (3) HRP20040626B9 (es)
HU (5) HU230576B1 (es)
LT (1) LT2264050T (es)
LU (1) LU91814I2 (es)
ME (1) ME00126B (es)
MX (1) MXPA04005364A (es)
NL (1) NL300480I2 (es)
NZ (2) NZ567688A (es)
PL (3) PL214803B1 (es)
PT (3) PT2264050T (es)
RS (1) RS51288B (es)
SI (3) SI1487483T1 (es)
TW (1) TWI314580B (es)
WO (1) WO2003049703A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CN1749397B (zh) * 2004-08-18 2010-12-08 金宁一 共表达猪圆环病毒及口蹄疫病毒的二联重组活载体疫苗
HUE033621T2 (en) 2004-12-30 2017-12-28 Boehringer Ingelheim Vetmedica Inc PCV2 immunogenic compositions and methods for preparing such compositions
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN1328373C (zh) * 2005-04-07 2007-07-25 南京农业大学 猪ⅱ型圆环病毒重组腺病毒
MX2007016083A (es) * 2005-06-24 2008-03-10 Intervet Int Bv Vacunas quimericas inactivadas y metodos relacionados de uso.
RU2389506C2 (ru) 2005-09-09 2010-05-20 Интервет Интернэшнл Б.В. Вакцина против рсv-2
MX356667B (es) 2005-12-29 2018-06-08 Boehringer Ingelheim Vetmedica Inc Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
KR101436794B1 (ko) * 2005-12-29 2014-09-04 베링거잉겔하임베트메디카인코퍼레이티드 다가 ｐｃｖ2 면역원성 조성물 및 이러한 조성물의 제조방법
JP4625485B2 (ja) * 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2094872T4 (da) * 2006-12-15 2020-05-18 Boehringer Ingelheim Animal Health Usa Inc Behandling af anti-PCV2-antistofseropositive svin med PCV2-antigen
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
MX2009012793A (es) * 2007-05-30 2010-03-26 Wyeth Llc Poxvirus de mapache que expresa genes de virus porcino.
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
UA98812C2 (ru) * 2007-11-06 2012-06-25 Вайет Ллк Авирулентная активированная живая вакцина mycoplasma hyopneumoniae
BRPI0821286A8 (pt) * 2007-12-21 2017-08-15 Wyeth Llc Métodos e composições para imunizar porcos contra circovirus suino
CN101932336B (zh) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 有外来氨基酸插入的pcv2 orf2病毒样颗粒
WO2009126356A2 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
WO2009103037A1 (en) * 2008-02-15 2009-08-20 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
WO2009128878A1 (en) * 2008-04-16 2009-10-22 Virginia Tech Intellectual Properties, Inc. CHIMERIC PORCINE CIRCOVIRUS PCV2Gen-1Rep AND USES THEREOF
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
SI2547770T1 (sl) 2010-03-16 2020-07-31 Virginia Tech Intellectual Properties, Inc. Vakcina atenuiranega živega himernega prašičjega virusa
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
EP2660356A4 (en) 2010-12-28 2014-07-09 Jx Nippon Oil & Energy Corp ORGANIC COMPOUND HYDROGENATION DEVICE AND HYDROGENATION METHOD
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
UA113192C2 (xx) 2011-12-06 2016-12-26 Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2)
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
KR102217387B1 (ko) * 2013-03-11 2021-02-19 주식회사 중앙백신연구소 재조합 효모 전세포(yeast whole cell)을 이용한 돼지 써코바이러스(PCV2) 서브유닛 백신과 그의 제조 방법
CN105579060B (zh) 2013-09-25 2021-03-16 硕腾服务有限责任公司 Pcv2b趋异株疫苗组合物以及使用方法
CA2924228C (en) 2013-10-02 2024-01-16 Boehringer Ingelheim Vetmedica, Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
CN103602759B (zh) * 2013-11-22 2015-09-23 福建省农业科学院畜牧兽医研究所 一种区别鸭圆环病毒和鹅圆环病毒的pcr-rflp方法
RU2712155C2 (ru) 2013-12-03 2020-01-24 Интервет Интернэшнл Б.В. Вакцина против цирковируса свиней 2 типа
EA201800494A1 (ru) * 2016-03-07 2019-07-31 Вирджиния Тех Интеллектуал Пропертис, Инк. Вакцины против химерного цирковируса свиней типа 2 (pcv2)
CN106497892A (zh) * 2016-09-07 2017-03-15 扬州大学 带KT3标签的重组病毒rPCV2‑KT3的构建方法
EA202092216A1 (ru) 2018-03-26 2021-06-11 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Способ получения иммуногенной композиции
CN112898435B (zh) * 2021-01-14 2023-03-31 山西农业大学 一种可溶性融合蛋白DT390-Cap及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DK1037909T3 (da) * 1997-12-11 2007-10-08 Univ Saskatchewan Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin
US6287856B1 (en) 1998-03-13 2001-09-11 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
CA2413265A1 (en) 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
BR0111366A (pt) 2000-05-24 2003-05-20 Merial Sas Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
WO2001096377A2 (en) 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
DE10044648A1 (de) 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
EP1379671B1 (en) 2001-03-27 2009-05-06 University of Saskatchewan Methods to culture circovirus
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines

Also Published As

Publication number Publication date
AU2011200843A1 (en) 2011-03-17
SI1487483T1 (sl) 2011-03-31
CO5590938A2 (es) 2005-12-30
FR11C0014I1 (es) 2011-06-17
CY1111167T1 (el) 2014-04-09
CY2011004I1 (el) 2014-04-09
PL215058B1 (pl) 2013-10-31
EP1487483A2 (en) 2004-12-22
KR101014544B1 (ko) 2011-02-16
CN1620310B (zh) 2014-11-26
CN1620310A (zh) 2005-05-25
ATE487490T1 (de) 2010-11-15
EP2264050A3 (en) 2011-04-20
CN103536911B (zh) 2019-09-13
AU2008202333B2 (en) 2010-11-25
US7276353B2 (en) 2007-10-02
EP1487483A4 (en) 2006-02-15
ES2355814T3 (es) 2011-03-31
EP2263690A2 (en) 2010-12-22
ES2694505T3 (es) 2018-12-21
HUS2100036I1 (hu) 2021-09-28
TWI314580B (en) 2009-09-11
HUP0501000A2 (en) 2007-12-28
TW200307042A (en) 2003-12-01
EP2263689B1 (en) 2014-11-12
FR11C0014I2 (fr) 2022-03-11
DK2263689T3 (en) 2015-02-02
EP2263689A2 (en) 2010-12-22
WO2003049703A8 (en) 2005-12-01
CA2784260C (en) 2016-05-17
DE122011100001I1 (de) 2011-09-08
WO2003049703A2 (en) 2003-06-19
RS51288B (sr) 2010-12-31
CA2469599C (en) 2012-10-23
DK1487483T3 (da) 2011-02-21
EP2263690A3 (en) 2011-06-08
EP1487483B1 (en) 2010-11-10
ME00126B (me) 2010-10-10
NL300480I2 (es) 2016-11-01
EP2264050A2 (en) 2010-12-22
BRPI0214919B1 (pt) 2015-09-15
LT2264050T (lt) 2018-11-26
WO2003049703A3 (en) 2004-09-30
KR20040086243A (ko) 2004-10-08
HRP20040626B9 (hr) 2016-09-23
PT2264050T (pt) 2018-11-21
JP4623964B2 (ja) 2011-02-02
HU228584B1 (en) 2013-04-29
HRP20140003B1 (hr) 2020-10-16
NZ533256A (en) 2008-06-30
HK1151988A1 (en) 2012-02-17
US20030170270A1 (en) 2003-09-11
BE2011C008I2 (es) 2022-02-02
SI2263689T1 (sl) 2015-03-31
HUP1300097A2 (en) 2007-12-28
PL395509A1 (pl) 2011-12-19
BR0214919A (pt) 2006-05-30
HU230576B1 (hu) 2017-01-30
SI2264050T1 (sl) 2018-12-31
EP2264050B1 (en) 2018-08-08
AU2002362147B2 (en) 2008-03-13
NZ567688A (en) 2009-09-25
DE60238278D1 (de) 2010-12-23
PT2263689E (pt) 2015-02-13
AU2002362147A1 (en) 2003-06-23
CN103536911A (zh) 2014-01-29
AU2011200843B2 (en) 2012-01-19
CY1121112T1 (el) 2019-12-11
HRP20140003A2 (hr) 2014-11-07
HRP20040626B1 (hr) 2016-08-26
PL374382A1 (en) 2005-10-17
AU2008202333A1 (en) 2008-06-19
HRP20140002A2 (hr) 2014-11-07
EP3388515A1 (en) 2018-10-17
AU2002362147C1 (en) 2012-05-17
CA2469599A1 (en) 2003-06-19
RS51704A (en) 2006-10-27
HU231162B1 (hu) 2021-05-28
CY2011004I2 (el) 2015-10-07
ES2529726T3 (es) 2015-02-25
LU91814I2 (fr) 2011-07-04
CA2784260A1 (en) 2003-06-19
HU231018B1 (hu) 2019-11-28
PT1487483E (pt) 2011-02-10
EP2263689A3 (en) 2011-04-20
PL395510A1 (pl) 2011-12-19
HRP20040626A2 (en) 2006-03-31
JP2005511075A (ja) 2005-04-28
MEP17708A (en) 2010-06-10
DK2264050T3 (en) 2018-12-03
HRP20140002B1 (hr) 2020-10-16
PL214803B1 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
MXPA04005364A (es) Clones de acido desoxirribonucleico infeccioso quimericos, circovirus de porcino quimericos y usos de los mismos.
WO2005092069A3 (en) Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
WO2011116094A3 (en) Live attenuated chimeric porcine circovirus vaccine
HUP0003756A2 (hu) Újonnan izolált, sertésből származó cirkovírusok, vakcinák és diagnosztikai reagensek
WO2017187277A3 (en) Chimeric porcine circovirus type 2 (pcv2) vaccines
PL345948A1 (en) Porcine circovirus and parvovirus vaccine
DK1037909T3 (da) Postweaning multisystemisk wasting-syndromvirus (PMWS) fra svin
AU2009236669A1 (en) Chimeric porcine circovirus PCV2Gen-1Rep and uses thereof
EP2155246B1 (en) Production of a homogeneous cell line highly permissive to porcine circovirus type 2 (pcv2) infection
CY1116098T1 (el) Χιμαιρικοι μολυσματικοι κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων

Legal Events

Date Code Title Description
FG Grant or registration